ONC201 treatment previously was able to significantly reduce MYCN protein expression, inhibit tumor formation, and reactivate alpha thalassemia mental retardation X-linked (ATRX) expression in MYCN-amplified NB cell-derived xenograft tumors [5]. This evidence concerns the gene ATRX and neuroblastoma.